gutflix
GI learning, personalised

Summary

REAL-WORLD EFFECTIVENESS AND SAFETY IN UPADACITINIB-TREATED PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PROFUNDUS STUDY

Smitha Suravaram

UEG Week Berlin 2025 | Poster

IBD

October 7, 2025

The PROFUNDUS interim analysis reports real-world effectiveness and safety of upadacitinib in 490 patients with moderate-to-severe ulcerative colitis over six months.

KEY POINTS

- Among evaluable patients, the median time to first clinical response was 4 days, and 79.6% achieved clinical response by the end of induction (week 8 or 16).
- At baseline, 51.3% of patients had intolerance or inadequate response to advanced therapies, and 13.1% had failed at least one prior JAK inhibitor.
- Through week 26, serious adverse events occurred in 5.5% of patients, with 2.2% considered possibly treatment-related; one death (drowning) was assessed as unrelated to study drug.
- The study enrolled 490 patients across 16 countries with median age 39 years, 43.3% female, and mean disease duration 7.6 years.
- Clinicians managing moderate-to-severe ulcerative colitis patients, particularly those with prior advanced therapy exposure, may find this real-world evidence relevant.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/3abdf676-a814-11f0-8efc-0242ac140006

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.